尤物视频污,99热99热99超碰,精品久久久久女少妇,少妇精品无码,日B视屏久久香色,亚洲美女午夜福利av,国产美女被操,国产九九精品,国产久久色情

Hubei Huabo Pharmaceutical Technology Co., Ltd. was established on March 7, 2022, located in the Saifu Technology Industrial Park (a provincial-level park) in Yanglubu, Yingcheng City, Hubei Province. The factory covers an area of 130 acres with a total investment of 300 million RMB. It is a specialized enterprise engaged in the production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) such as Ribavirin, Gliptins, Statins, and Sartans. In 2023, it was listed as a key investment promotion project in Yingcheng City, receiving encouragement from national policies and strong support from the local government. The company's core management team comes from a listed pharmaceutical company in Zhejiang. In September 2022, Huabo Pharmaceutical acquired a controlling stake in Hubei Zhicheng Chemical Technology Co., Ltd., which was established on November 19, 2002. Hubei Zhicheng is a "National High-Tech Enterprise" and was recognized as a "Provincial Invisible Champion Enterprise" in 2018 and a "Provincial Technology Little Giant Enterprise" in 2019 for its methyl ester products. It is a leading enterprise in the methyl ester product segment of China's fine chemical industry and has passed ISO9001 quality system certification.

The company's main business is the research and development, production, and sales of pharmaceutical intermediates. It maintains long-term and stable business relationships with well-known pharmaceutical companies both domestically and internationally. Simultaneously, it is committed to building a high-end CRO/CMC manufacturing service platform for advanced raw materials. Through specialized, high-standard process research, quality management, and project management systems, the company focuses on the R&D and production of high-technical-barrier, high-difficulty, and complex chiral drug APIs and intermediates. Its products cover areas such as antiviral, antitumor, diabetes, and cardiovascular diseases. To date, it has completed process R&D and extended over 20 products into APIs and intermediates, with 10 of them having industrial production capabilities. Products are sold in both domestic and international markets. The company's mission is to consistently strive to become a responsible and first-class pharmaceutical enterprise that satisfies customers, employees, and gains social recognition.